{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:46:07Z","timestamp":1768815967133,"version":"3.49.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T00:00:00Z","timestamp":1523836800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1007\/s00277-018-3328-3","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T11:57:46Z","timestamp":1523879866000},"page":"1619-1626","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Yttrium-90 ibritumomab tiuxetan (Zevalin) followed by BEAM (Z-BEAM) conditioning regimen and autologous stem cell transplantation (ASCT) in relapsed or refractory high-risk B-cell non-Hodgkin lymphoma (NHL): a single institution Italian experience"],"prefix":"10.1007","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-4208","authenticated-orcid":false,"given":"Chiara","family":"Ciochetto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Passera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Bell\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Benevolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carola","family":"Boccomini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Castellino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annalisa","family":"Chiappella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Freilone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maura","family":"Nicolosi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorella","family":"Orsucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Pregno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianni","family":"Bisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,4,16]]},"reference":[{"issue":"116","key":"3328_CR1","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"23","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019 Etudes des Lymphomes de l\u2019Adulte. Blood 23(116):2040\u20132045","journal-title":"Blood"},{"issue":"9880","key":"3328_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","volume":"381","author":"D Cunningham","year":"2013","unstructured":"Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 381(9880):1817\u20131826","journal-title":"Lancet"},{"issue":"12","key":"3328_CR3","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","volume":"13","author":"N Schmitz","year":"2012","unstructured":"Schmitz N, Nickelsen M, Ziepert M, Haenel M, Borchmann P, Schmidt C, Viardot A, Bentz M, Peter N, Ehninger G, Doelken G, Ruebe C, Truemper L, Rosenwald A, Pfreundschuh M, Loeffler M, Glass B, German High-Grade Lymphoma Study Group (DSHNHL) (2012) Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). Lancet Oncol 13(12):1250\u20131911","journal-title":"Lancet Oncol"},{"issue":"27","key":"3328_CR4","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Bri\u00e8re J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28(27):4184\u20134190","journal-title":"J Clin Oncol"},{"key":"3328_CR5","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","volume":"18","author":"N Mounier","year":"2012","unstructured":"Mounier N, Canals C, Gisselbrecth C (2012) High dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: ana analysis base on data from the European Bloos and marrow transplantation registry. Biol Blood Marrow Transaplant 18:788\u2013793","journal-title":"Biol Blood Marrow Transaplant"},{"issue":"2","key":"3328_CR6","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1200\/JCO.2001.19.2.406","volume":"19","author":"JM Vose","year":"2001","unstructured":"Vose JM, Zhang MJ, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO, Pavlovsky S, Keating A, Yanes B, van Besien K, Armitage JO, Horowitz MM, Others of the Autologous Blood and Marrow Transplant Registry Lymphoma Working Committee (2001) Autologous transplantation for diffuse aggressive non-Hodgkin\u2019s lymphoma in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 19(2):406\u2013413","journal-title":"J Clin Oncol"},{"issue":"1","key":"3328_CR7","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdg008","volume":"14","author":"MD Caballero","year":"2003","unstructured":"Caballero MD, P\u00e9rez-Sim\u00f3n JA, Iriondo A, Lahuerta JJ, Sierra J, Mar\u00edn J, Gandarillas M, Arranz R, Zuazu J, Rubio V, Fern\u00e1ndez de Sevilla A, Carreras E, Garc\u00eda-Conde J, Garc\u00eda-Lara\u00f1a J, Grande C, Sureda A, Vidal MJ, Rif\u00f3n J, P\u00e9rez-Equiza C, Varela R, Moraleda JM, Garc\u00eda Ru\u00edz JC, Alb\u00f3 C, Cabrera R, San Miguel JF, Conde E (2003) High dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish cooperative group. Ann Oncol 14(1):140\u2013151","journal-title":"Ann Oncol"},{"issue":"11","key":"3328_CR8","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1080\/10428190701573273","volume":"48","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Nagler A (2007) Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma. Leuk Lymphoma 48(11):2110\u20132120","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"3328_CR9","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1200\/JCO.2003.08.043","volume":"21","author":"TE Witzig","year":"2003","unstructured":"Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, Lister J, Multani PS (2003) Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin\u2019s lymphoma. J Clin Oncol 21(7):1263\u20131270","journal-title":"J Clin Oncol"},{"issue":"1","key":"3328_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1200\/JCO.2007.11.9248","volume":"26","author":"A Krishnan","year":"2008","unstructured":"Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, Rodriguez R, Spielberger RT, Falk P, Palmer JM, Forman SJ (2008) Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and highdose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 26(1):90\u201395","journal-title":"J Clin Oncol"},{"issue":"8","key":"3328_CR11","doi-asserted-by":"publisher","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","volume":"106","author":"A Nademanee","year":"2005","unstructured":"Nademanee A, Forman S, Molina A et al (2005) A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 106(8):2896\u20132902","journal-title":"Blood"},{"issue":"19","key":"3328_CR12","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1002\/cncr.27418","volume":"118","author":"A Shimoni","year":"2012","unstructured":"Shimoni A, Avivi I, Rowe JM, Yeshurun M, Levi I, Or R, Patachenko P, Avigdor A, Zwas T, Nagler A (2012) A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer 118(19):4706\u20134714","journal-title":"Cancer"},{"key":"3328_CR13","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjh.13803","volume":"172","author":"M Musso","year":"2016","unstructured":"Musso M, Messina G, Di Renzo N et al (2016) Improved outcome of patients with relapsed\/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chempotherapy regimen. Br J Heamatol 172:111\u2013121","journal-title":"Br J Heamatol"},{"issue":"5","key":"3328_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"4","key":"3328_CR15","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.exphem.2007.01.043","volume":"35","author":"A Shimoni","year":"2007","unstructured":"Shimoni A, Zwas ST, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, Avigdor A, Ben-Bassat I, Nagler A (2007) Yttrium 90 Ibritumomab Tiuxetan (Zevalin) combined with high dose BEAM chemotherapy and autologous stem cell transplantation for chemorefractory aggressive non-Hodgkin\u2019s lymphoma. Exp Hematol 35(4):534\u2013540","journal-title":"Exp Hematol"},{"issue":"3","key":"3328_CR16","doi-asserted-by":"publisher","first-page":"505","DOI":"10.3324\/haematol.2013.093450","volume":"99","author":"J Briones","year":"2014","unstructured":"Briones J, Novelli S, Garcia-Marco JA, Tomas JF, Bernal T, Grande C, Canales MA, Torres A, Moraleda JM, Panizo C, Jarque I, Palmero F, Hernandez M, Gonzalez-Barca E, Lopez D, Caballero D, on behalf of GELTAMO (2014) Autologous stem cell transplantation after conditioning with yttrium 90 Ibritumomab Tiuxetan plus BEAM in refractory non-Hodgkin\u2019s diffuse large B cell lymphoma: results of a prospective, multicenter, phase II clinical trial. Haematologica 99(3):505\u2013510","journal-title":"Haematologica"},{"key":"3328_CR17","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, Fenske T, Horowitz M, Fisher R, Tomblyn M (2013) Phase III randomized study of rituximab carmustine, etoposide cytarabine and melfalan (BEAM) compared with iodine-131 Tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31:1662\u20131668","journal-title":"J Clin Oncol"},{"key":"3328_CR18","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.bbmt.2017.03.004","volume":"23","author":"AY Krishnan","year":"2017","unstructured":"Krishnan AY, Palmer J, Nademanee AP, Chen R, Popplewell LL, Tsai NC, Sanchez JF, Simpson J, Spielberger R, Yamauchi D, Forman SJ (2017) Phase II study of yttrium-90 ibritumomab tiuxetan plus high dose BCNU, etoposide, cytarabine and melphalan for non-Hodgkin lymphoma: the role of hystology. Biol Bone Marrow Transplant 23:922\u2013929","journal-title":"Biol Bone Marrow Transplant"},{"issue":"7","key":"3328_CR19","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1182\/blood.V96.7.2399","volume":"96","author":"T Kewalramani","year":"2000","unstructured":"Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S, Priovolos AC, Qin J, Lyons NC, Yahalom J, Nimer SD, Moskowitz CH (2000) High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin lymphoma: an intention-to-treat analysis. Blood 96(7):2399\u20132404","journal-title":"Blood"},{"issue":"27","key":"3328_CR20","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1200\/JCO.2006.09.2882","volume":"25","author":"MS Czuczman","year":"2007","unstructured":"Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, Vo K, Molina A (2007) Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol 25(27):4285\u20134292","journal-title":"J Clin Oncol"},{"issue":"10","key":"3328_CR21","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1200\/JCO.2008.19.2245","volume":"27","author":"JN Winter","year":"2009","unstructured":"Winter JN, Inwards DJ, Spies S, Wiseman G, Patton D, Erwin W, Rademaker AW, Weitner BB, Williams SF, Tallman MS, Micallef I, Mehta J, Singhal S, Evens AM, Zimmer M, Molina A, White CA, Gordon LI (2009) Yttrium-90 ibritumomab tiuxetan doses calculated to deliver up to 15 Gy to critical organs may be safely combined with high-dose BEAM and autologous transplantation in relapsed or refractory B-cell non- Hodgkin\u2019s lymphoma. J Clin Oncol 27(10):1653\u20131659","journal-title":"J Clin Oncol"},{"key":"3328_CR22","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip T, Guglielmi C, Hagenbeek A, Somers R, van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn JY, Harousseau JL, Coiffier B, Biron P, Mandelli F, Chauvin F (1995) Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N Engl J Med 333:1540\u20131545","journal-title":"N Engl J Med"},{"issue":"9","key":"3328_CR23","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1002\/cncr.23861","volume":"113","author":"E Derenzini","year":"2008","unstructured":"Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M, Alinari L, Venturini F, Gandolfi L, Baccarani M, Zinzani PL (2008) Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation out-come in aggressive B-cell non-Hodgkin lymphoma. Cancer 113(9):2496\u20132503","journal-title":"Cancer"},{"key":"3328_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s00259-009-1258-y","volume":"37","author":"LS Poulou","year":"2010","unstructured":"Poulou LS, Thanos L, Ziakas PD (2010) Unifying the predictive value of pretransplant FDG PET in patients with lymphoma: a review and meta-analysis of published trials. Eur J Nucl Med Mol Imaging 37:156\u2013162","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3328_CR25","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1182\/blood-2005-11-006957","volume":"109","author":"BW Schot","year":"2007","unstructured":"Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W, Vellenga E (2007) Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109:486\u2013491","journal-title":"Blood"},{"key":"3328_CR26","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U, van den Neste E, Kuruvilla J, Westin J, Link BK, Hay A, Cerhan JR, Zhu L, Boussetta S, Feng L, Maurer MJ, Navale L, Wiezorek J, Go WY, Gisselbrecht C (2017) Outcome in refractory diffuse large B-cell lymphoma: results from the international Scholar-1 study. Blood 130:1800\u20131808","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3328-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3328-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T19:12:13Z","timestamp":1571166733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3328-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,16]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["3328"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3328-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,16]]},"assertion":[{"value":"3 November 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Umberto Vitolo was on the advisory committee of Roche, Janssen and received a lecture fee from Roche, Celgene, Janssen, Takeda, and Gilead.The remaining authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}